Through an analysis of how the cysteine protease inhibitor E64 improves infection outcomes in a murine model of E. faecalis CAUTI, this study has identified potential targets for the development of antibiotic-sparing therapeutics for the treatment of CAUTI caused by multidrug-resistant uropathogens. Here, CTSB is linked to infection.